Simultaneous reconstitution of multiple cytomegalovirus-specific CD8 + cell populations with divergent functionality in hematopoietic stem-cell transplant recipients

Journal of Infectious Diseases

Volumn 191, Issue 6, 2005, Pages 977-984

  Lacey, Simon F ^a,d   Martinez, Joy ^a   Gallez Hawkins, Ghislaine ^b   Thao, Lia ^b   Longmafe, Jeff ^c   Haq, Wahajul ^a   Spielberger, Ricardo ^d   Forman, Stephen J ^d   Zaia, John A ^b   Diamond, Don J ^a  

^a Laboratory of Vaccine Research   (United States)

^b Division of Virology   (Japan)

^c Beckman Research Institute of City of Hope   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GENE PRODUCT; LEUKOCYTE ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; VIRUS PROTEIN;

ADULT; ALLELE; ANTIGEN SPECIFICITY; ARTICLE; CELL POPULATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LYSOSOME MEMBRANE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, CD; BLOOD DONORS; CD8-POSITIVE T-LYMPHOCYTES; CELL DEGRANULATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; EPITOPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 20044380510     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428136     Document Type: Article

References (44)

1. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97:1232-40.
2. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21:597-605.
3. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98:1358-64.
4. Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1:774-6.
5. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.
6. Akiyama Y, Maruyama K, Mochizuki T, Sasaki K, Takaue Y, Yamaguchi K. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol Lett 2002; 83:21-30.
7. Diamond DJ, York J, Sun J, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90:1751-67.
8. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002; 185:1709-16.
9. Kern F, Faulhaber N, Khatamzas E, et al. Measurement of anti-human cytomegalovirus T cell reactivity in transplant recipients and its potential clinical use: a mini-review. Intervirology 1999; 42:322-4.
10. La Rosa C, Krishnan R, Markel S, et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 2001; 97:1776-86.
11. + T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003; 64:440-52.
12. Masuoka M, Yoshimuta T, Hamada M, et al. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Viral Immunol 2001; 14:369-77.
13. Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J Virol 1999; 73:2099-108.
14. Wills MR, Carmichael AJ, Mynard K, et al. The human CTL response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J Virol 1996; 70:7569-79.
15. Frankenberg N, Pepperl-Klindworth S, Meyer RG, Plachter B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 2002; 295:208-16.
16. Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000; 181:1537-46.
17. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999; 73:8179-84.
18. + T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 2002; 185:1025-34.
19. Prod'homme V, Retiere C, Imbert-Marcille BM, Bonneville M, Hallet MM. Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1 (315-324) epitope of human cytomegalovirus. J Immunol 2003; 170:2030-6.
20. Retiere C, Prod'homme V, Imbert-Marcille BM, Bonneville M, Vie H, Hallet MM. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J Virol 2000; 74:3948-52.
21. Li C, Yang X, Tu W, Riddell SR. Human cytomegalovirus matrix protein pp150 is efficiently presented as one of target antigens for cytotoxic T lymphocyte recognition. Chin Med J (Engl) 1997; 110:397-400.
22. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52:165-73.
23. Wang Z, La Rosa C, Mekhoubad S, et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 2004; 104:847-56.
24. +-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77:5226-40.
25. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
26. + T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004; 172:6407-17.
27. + T cells. J Exp Med 2004; 199:925-36.
28. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9:1377-82.
29. Krausa P, Browning MJ. A comprehensive PCR-SSP typing system for identification of HLA-A locus alleles. Tissue Antigens 1996; 47:237-44.
30. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90:1751-67.
31. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52:165-73.
32. La Rosa C, Lacey SF, Brewer JC, et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002; 100:3681-9.
33. + T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002; 74:722-32.
34. + T cell subsets as a strong adaptive immune response to cytomegalovirus. J Infect Dis 2001; 184:256-67.
35. + T lymphocytes. J Immunol 2001; 167:181-7.
36. Villacres MC, Lacey SF, Auge C, Longmate J, Leedom JM, Diamond DJ. Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity. J Infect Dis 2003; 188:908-18.
37. + T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98:754-61.
38. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12.
39. + cytotoxic T cell response in natural infection. Blood 2004; 104:1075-82.
40. Cobbold M, Khan N, Piper K, et al. The immunodominance of HCMV immediate early (IE1) protein in patients following stem cell transplantation. Clin Invest Med 2004; 27:10c.
41. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002; 2:831-44.
42. Sweet C. The pathogenicity of cytomegalovirus. FEMS Microbiol Rev 1999; 23:457-82.
43. Hengel H, Reusch U, Geginat G, et al. Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J Virol 2000; 74:7861-8.
44. Del Val M, Munch K, Reddehase MJ, Koszinowski UH. Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell 1989; 58:305-15.